Icon Plc $ICLR Shares Sold by Blair William & Co. IL

Blair William & Co. IL decreased its stake in shares of Icon Plc (NASDAQ:ICLR) by 4.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,174 shares of the medical research company’s stock after selling 1,204 shares during the quarter. Blair William & Co. IL’s holdings in Icon were worth $3,371,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of ICLR. Ninety One UK Ltd increased its stake in Icon by 2.6% during the 2nd quarter. Ninety One UK Ltd now owns 2,993,652 shares of the medical research company’s stock valued at $435,427,000 after purchasing an additional 75,465 shares in the last quarter. Ninety One North America Inc. increased its stake in Icon by 20.5% during the 2nd quarter. Ninety One North America Inc. now owns 428,851 shares of the medical research company’s stock valued at $62,376,000 after purchasing an additional 72,945 shares in the last quarter. Running Oak Capital LLC increased its stake in Icon by 29.2% during the 2nd quarter. Running Oak Capital LLC now owns 107,218 shares of the medical research company’s stock valued at $15,595,000 after purchasing an additional 24,260 shares in the last quarter. Truist Financial Corp increased its stake in Icon by 112.0% during the 2nd quarter. Truist Financial Corp now owns 37,456 shares of the medical research company’s stock valued at $5,448,000 after purchasing an additional 19,789 shares in the last quarter. Finally, Canoe Financial LP increased its stake in Icon by 10.3% during the 2nd quarter. Canoe Financial LP now owns 193,851 shares of the medical research company’s stock valued at $28,196,000 after purchasing an additional 18,174 shares in the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on ICLR shares. Jefferies Financial Group lowered shares of Icon from a “buy” rating to a “hold” rating and cut their price objective for the stock from $220.00 to $175.00 in a research note on Tuesday, September 9th. Baird R W upgraded shares of Icon from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 24th. Weiss Ratings reiterated a “hold (c)” rating on shares of Icon in a research note on Wednesday, October 8th. Evercore ISI increased their price objective on shares of Icon from $170.00 to $240.00 and gave the stock an “outperform” rating in a research note on Friday, July 25th. Finally, Rothschild & Co Redburn upgraded shares of Icon from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $184.00 to $236.00 in a research note on Wednesday, September 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $210.64.

Icon Stock Up 1.4%

ICLR stock opened at $186.05 on Tuesday. The firm has a market cap of $15.03 billion, a PE ratio of 19.14, a P/E/G ratio of 2.72 and a beta of 1.23. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.29 and a current ratio of 1.29. The firm’s fifty day moving average is $174.99 and its 200 day moving average is $156.75. Icon Plc has a one year low of $125.10 and a one year high of $301.45.

Icon (NASDAQ:ICLR) last released its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $3.26 EPS for the quarter, beating the consensus estimate of $3.18 by $0.08. The company had revenue of $2.02 billion for the quarter, compared to analyst estimates of $1.98 billion. Icon had a net margin of 9.82% and a return on equity of 10.95%. The firm’s revenue was down 4.8% on a year-over-year basis. During the same quarter last year, the business earned $3.75 earnings per share. Icon has set its FY 2025 guidance at 13.000-14.000 EPS. On average, research analysts forecast that Icon Plc will post 13.38 EPS for the current year.

About Icon

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.